Introduction Sironax Ltd. is a pharmaceutical company headquartered in Beijing, China. Founded in 2017 by Dr. Xiao Dong Wang and Zhi Yuan Zhang currently serves as the Chief Executive Officer of the company. Sironax Ltd. focuses on the development of small molecule inhibitors based on Dr. Wang Xiaodong's groundbreaking discoveries in various areas of cell death, including apoptosis and programmed necrosis. The company is dedicated to addressing a range of significant diseases.
These inhibitors are designed to target various diseases, including neurodegenerative conditions such as Alzheimer's disease, multiple sclerosis, and Parkinson's disease; ischemic diseases like stroke, renal ischemia, and myocardial ischemia; as well as inflammatory disorders such as colitis, psoriasis, and sepsis. Sironax Ltd.'s research capabilities span all aspects of drug development, including small molecule screening, chemical synthesis, molecular and cellular biology research, animal efficacy evaluation, pharmacokinetics-pharmacodynamics analysis, and preclinical toxicology analysis. |